Oka M, Itoh Y, Shimidzu T, Ukai Y, Yoshikuni Y, Kimura K
Research Laboratories, Nippon Shinyaku Co., Ltd., Nishiohji Hachijo Minami-ku, Kyoto, Japan.
Brain Res. 1997 Apr 18;754(1-2):121-30. doi: 10.1016/s0006-8993(97)00064-4.
The effect of a novel cognition enhancer [(+)-5-oxo-D-prolinepiperidinamide monohydrate] (NS-105) on cAMP formation was investigated in both slices and membranes of the rat cerebral cortex. NS-105 (10(-8)-10(-6) M) inhibited forskolin-stimulated cAMP formation in membranes, however, the compound significantly enhanced the cAMP formation in pertussis toxin-pre-treated membranes, an action that was abolished by cholera toxin. In contrast, in digitonin-permeabilized membranes, NS-105 had no influence on Mn2+-stimulated cAMP formation. Both of the inhibitory and facilitatory actions of NS-105 on cAMP formation were mimicked by a metabotropic glutamate receptor (mGluR) agonist (1S,3R)-1-aminocyclopentane-1,3-dicarboxylic acid (1S,3R-ACPD) and an adrenergic alpha2 agonist UK-14,304, and blocked by a mGluR antagonist 2-amino-3-phosphonopropanoate but not by an alpha2 antagonist yohimbine. In cortical slices, NS-105 (10(-8)-10(-7) M) inhibited forskolin-stimulated cAMP accumulation but enhanced isoproterenol-stimulated cAMP accumulation, as did by a GABA(B) agonist (-)baclofen. On the other hand, (-)baclofen, while it significantly inhibited cAMP accumulation in slices, did no longer inhibit cAMP accumulation, when treated with NS-105 (10(-8)-10(-5) M). Similarly, (-)baclofen-induced inhibition of the cAMP accumulation was reversed by 1S,3R-ACPD and UK-14,304. NS-105 (10(-6)) increased [35S]GTPgammaS binding in the intact but not digitonin-permeabilized cortical membranes, as produced by UK-14,304, although the compound (10(-9)-10(-3) M) had no influence on various neurotransmitter receptor bindings, including alpha2 receptors. These results suggest that NS-105 modulates adenylate cyclase activity by stimulating mGluRs which might coupled to both Gi/Go and Gs.
研究了一种新型认知增强剂[(+)-5-氧代-D-脯氨酸哌啶酰胺一水合物](NS-105)对大鼠大脑皮质切片和膜中cAMP形成的影响。NS-105(10^-8 - 10^-6 M)抑制膜中福斯高林刺激的cAMP形成,然而,该化合物显著增强百日咳毒素预处理膜中的cAMP形成,霍乱毒素可消除这一作用。相反,在洋地黄皂苷通透的膜中,NS-105对Mn2+刺激的cAMP形成没有影响。NS-105对cAMP形成的抑制和促进作用均被代谢型谷氨酸受体(mGluR)激动剂(1S,3R)-1-氨基环戊烷-1,3-二羧酸(1S,3R-ACPD)和肾上腺素能α2激动剂UK-14,304模拟,并被mGluR拮抗剂2-氨基-3-膦酰丙酸阻断,但不被α2拮抗剂育亨宾阻断。在皮质切片中,NS-105(10^-8 - 10^-7 M)抑制福斯高林刺激的cAMP积累,但增强异丙肾上腺素刺激的cAMP积累,γ-氨基丁酸B(GABA(B))激动剂(-)巴氯芬也有同样的作用。另一方面,(-)巴氯芬虽然在切片中显著抑制cAMP积累,但在用NS-105(10^-8 - 10^-5 M)处理后不再抑制cAMP积累。同样,(-)巴氯芬诱导的cAMP积累抑制被1S,3R-ACPD和UK-14,304逆转。NS-105(10^-6)增加完整皮质膜而非洋地黄皂苷通透皮质膜中的[35S]GTPγS结合,这是由UK-14,304产生的,尽管该化合物(10^-9 - 10^-3 M)对包括α2受体在内的各种神经递质受体结合没有影响。这些结果表明,NS-105通过刺激可能与Gi/Go和Gs偶联的mGluRs来调节腺苷酸环化酶活性。